Dystrophin– tag –
-
Precision BioSciences Initiates Clinical Trial for ARCUS Nuclease Gene Editing Therapy PBGENE-DMD in DMD
CRISPR Medicine News USA Overview Precision BioSciences has dosed the first patient in its Phase 1/2 clinical trial for PBGENE-DMD, a gene editing therapy for Duchenne muscular dystrophy (DMD). This therapy utilizes two ARCUS nucleases t... -
Precision BioSciences Initiates Phase 1/2 FUNCTION-DMD Clinical Trial for PBGENE-DMD Gene Therapy: Applicable to 60% of DMD Patients, Initial Safety Data Expected by Year-End
Precision BioSciences, Inc. (Press Release) USA Overview Precision BioSciences announced the initiation of patient dosing in its Phase 1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, an in vivo gene editing therapy for Duchenne muscular ... -
SonoThera Raises $125M Series B to Advance Safer Ultrasound-Mediated Gene Therapies for Duchenne Muscular Dystrophy and ADPKD into Clinical Development
BioSpace USA Overview SonoThera has secured $125 million in Series B financing to advance its gene therapy programs for Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into clinical development.... -
UT MD Anderson Develops Exosome-Based Therapy for Duchenne Muscular Dystrophy, Delivering Full-Length DMD mRNA to Dramatically Restore Muscle Function In Vivo
Nature Biomedical Engineering (via The University of Texas MD Anderson Cancer Center) USA Overview Researchers at The University of Texas MD Anderson Cancer Center have developed a novel therapeutic platform utilizing engineered extracel... -
Precision BioSciences Unveils Promising Preclinical Data for In Vivo Gene Editing Therapy in Duchenne Muscular Dystrophy
Morningstar USA Overview Precision BioSciences has presented encouraging preclinical data for PBGENE-DMD, an in vivo gene editing therapy targeting Duchenne Muscular Dystrophy, at the 2026 ASGCT Annual Meeting. Early intervention in youn...
1